Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Andrea Giacomelli, Laura Pezzati & Stefano Rusconi. (2020) The crosstalk between antiretrovirals pharmacology and HIV drug resistance. Expert Review of Clinical Pharmacology 13:7, pages 739-760.
Read now
Read now
Ying Mu, Michelle Pham, Anthony T. Podany & Theodore J. Cory. (2020) Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection. Expert Opinion on Pharmacotherapy 21:4, pages 389-397.
Read now
Read now
Roger Bedimo, Lisa Rosenblatt & Joel Myers. (2016) Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. HIV Clinical Trials 17:6, pages 246-266.
Read now
Read now
Ed L. Wilkins, Calvin J. Cohen, Benoit Trottier, Stefan Esser, Don E. Smith, Bernhard Haas, Cynthia Brinson, Will Garner, Susan Chuck, David Thorpe & Shampa De-Oertel. (2016) Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. AIDS Care 28:3, pages 401-408.
Read now
Read now
Pornpimol Thamrongwonglert, Ploenchan Chetchotisakd, Siriluck Anunnatsiri & Piroon Mootsikapun. (2016) Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia. HIV Clinical Trials 17:1, pages 12-16.
Read now
Read now
Sheng-Li Li, Peng Xu, Lei Zhang, Gui-Xiang Sun & Zhao-Jun Lu. (2015) Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis. HIV Clinical Trials 16:1, pages 22-29.
Read now
Read now
Sheng-li Li, Peng Xu, Lei Zhang, Gui-xiang Sun & Zhao-jun Lu. (2014) Effectiveness and Safety of Rilpivirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive Adults Infected with HIV-1: A Meta-analysis. HIV Clinical Trials 15:6, pages 261-268.
Read now
Read now
Anthony M. Mills, Calvin Cohen, Edwin DeJesus, Cynthia Brinson, Scott Williams, Kitty L. Yale, Srini Ramanathan, Maggie H. Wang, Kirsten White, Susan K. Chuck & Andrew K. Cheng. (2013) Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens. HIV Clinical Trials 14:5, pages 216-223.
Read now
Read now
Articles from other publishers (49)
Pobitra Borah, Sangeeta Hazarika, Mohamed A. Morsy, Manoj Goyal, Ashna Chettri, Katharigatta N. Venugopala, Viresh Mohanlall, Pratap Chandra Acharya, Pran Kishore Deb & Raghu Prasad Mailavaram. 2023. Medicinal Chemistry of Chemotherapeutic Agents. Medicinal Chemistry of Chemotherapeutic Agents
319
359
.
Alessandro Cozzi-Lepri, Lars Peters, Annegret Pelchen-Matthews, Bastian Neesgaard, Stephane De Wit, Isik Somuncu Johansen, Simon Edwards, Christoph Stephan, Georgios Adamis, Therese Staub, Alexandra Zagalo, Pere Domingo, Daniel Elbirt, Katharina Kusejko, Johanna Brännström, Dzmitry Paduta, Tatyana Trofimova, Janos Szlavik, Kai Zilmer, Marcello Losso, Veerle Van Eygen, Helen Pai, Jens Lundgren, Amanda Mocroft, A. Harxhi, M. Losso, M. Kundro, B. Schmied, I. Karpov, A. Vassilenko, D. Paduto, V. M. Mitsura, N. Clumeck, S. De Wit, M. Delforge, V. Hadziosmanovic, J. Begovac, L. Machala, D. Jilich, J. Gerstoft, C. Pedersen, D. Sedlacek, G. Kronborg, T. Benfield, I. S. Johansen, L. Ostergaard, L. Wiese, N. F. Moller, L. N. Nielsen, K. Zilmer, Jelena Smidt, I. Aho, J. P. Viard, P. M. Girard, C. Pradier, E. Fontas, C. Duvivier, J. Rockstroh, O. Degen, C. Hoffmann, H. J. Stellbrink, C. Stefan, J. Bogner, G. Fätkenheuer, N. Chkhartishvili, H. Sambatakou, G. Adamis, N. Paissios, V. Uzdaviniene, T. Staub, S. Dragas, P. Reiss, J. Trajanovska, D. H. Reikvam, A. Maeland, J. Bruun, B. Knysz, B. Szetela, M. Inglot, E. Bakowska, R. Flisiak, A. Grzeszczuk, M. Parczewski, K. Maciejewska, B. Aksak-Was, M. Beniowski, E. Mularska, E. Jablonowska, J. Kamerys, K. Wojcik, I. Mozer-Lisewska, B. Rozplochowski, A. Zagalo, R. Radoi, C. Oprea, A. Yakovlev, T. Trofimora, I. Khromova, E. Kuzovatova, E. Borodulina, E. Vdoushkina, J. Ranin, J. Tomazic, J. M. Miro, M. Laguno, E. Martinez, F. Garcia, J. L. Blanco, M. Martinez-Rebollar, J. Mallolas, P. Callau, J. Rojas, S. Moreno, S. del Campo, A. Jou, R. Paredes, J. Puig, J. M. Llibre, J. R. Santos, P. Domingo, M. Gutierrez, G. M. Mateo, A. Sambeat, J. M. Laporte, V. Svedhem, A. Thalme, A. Sonnerborg, L. Flamholc, K. Kusejko, R. Weber, A. Calmy, H. Furrer, M. Battegay, P. Schmid, A. Kuznetsova, J. Mikhalik, M. Sluzhynska, A. Milinkovic, A. M. Johnson, E. Simons, S. Edwards, A. M. Phillips, A. Johnson, A. Mocroft, C. Orkin, A. Winston, A. Clarke & C. Leen. (2022) Observational cohort study of rilpivirine (RPV) utilization in Europe. AIDS Research and Therapy 19:1.
Crossref
Crossref
Katharina Nickel, Nicholas J. A. Halfpenny, Sonya J. Snedecor & Yogesh Suresh Punekar. (2021) Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infectious Diseases 21:1.
Crossref
Crossref
Panita Maturavongsadit, Roopali Shrivastava, Craig Sykes, Mackenzie L. Cottrell, Stephanie A. Montgomery, Angela D.M. Kashuba & S. Rahima Benhabbour. (2021) Biodegradable polymeric solid implants for ultra-long-acting delivery of single or multiple antiretroviral drugs. International Journal of Pharmaceutics 605, pages 120844.
Crossref
Crossref
Ke Zhang, Yang Zhang, Xinchao Liu, Aixin Li, Meixia Gao, Jianhua Hou, Chunxiang Guo, Tong Zhang, Hao Wu, Guanzhi Chen & Xiaojie Huang. (2021) Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Chloe Orkin, Kathleen E Squires, Jean-Michel Molina, Paul E Sax, Otto Sussmann, Gina Lin, Sushma Kumar, George J Hanna, Carey Hwang, Elizabeth Martin & Hedy Teppler. (2021) Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clinical Infectious Diseases 73:1, pages 33-42.
Crossref
Crossref
Sharlene Ho, Joshua Guoxian Wong, Oon Tek Ng, Cheng Chuan Lee, Yee Sin Leo, David Chien Boon Lye & Chen Seong Wong. (2020) Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults. AIDS Research and Therapy 17:1.
Crossref
Crossref
Shalini Behl, Abdu Adem, Arif Hussain & Jaipaul Singh. (2020) Effect of the anti-retroviral drug, rilpivirine, on human subcutaneous adipose cells and its nutritional management using quercetin. Molecular and Cellular Biochemistry 471:1-2, pages 1-13.
Crossref
Crossref
Christoph D Spinner & Tristan John Barber. (2020) Are 96-week data enough for doravirine to DRIVE FORWARD?. The Lancet HIV 7:1, pages e2-e3.
Crossref
Crossref
Jean-Michel Molina, Kathleen Squires, Paul E Sax, Pedro Cahn, Johan Lombaard, Edwin DeJesus, Ming-Tain Lai, Anthony Rodgers, Lisa Lupinacci, Sushma Kumar, Peter Sklar, George J Hanna, Carey Hwang, Elizabeth Anne Martin, Debbie P. Hagins, Olayemi O. Osiyemi, David James Prelutsky, Moti N. Ramgopal, Anthony John Scarsella, Robin Dretler, Edwin DeJesus, Christopher J. Bettacchi, James SimsIIIIII, Patrick G. Clay, Nicholaos C. Bellos, Melanie A. Thompson, Jose Montero, Cheryl K. McDonald, Catherine Creticos, David Shamblaw, Miguel Mogyoros, Antonio E. Terrelonge, Martin Valdes, Karen T. Tashima, William J. Robbins, Franco Antonio Felizarta, Richard A. Elion, Jihad Slim, Sandra S. Win, Sujata N. Lalla-Reddy, Peter Jerome Ruane, Anthony Mills, Jerry L. Cade, Craig A. Dietz, David Scott Rubin, Cynthia Mayer, Juan Carlos Rondon, Paul P. Cook, Eric Daar, Princy N. Kumar, Susan Swindells, Jose Guillermo Castro, Ivan Melendez-Rivera, Javier O. Morales-Ramirez, Lizette Santiago, Jorge L. Santana-Bagur, Marcelo Martins, Pedro Enrique Cahn, Gustavo D. Lopardo, Norma Porteiro, Mark Theo Bloch, David Alfred Baker, Norman Roth, Richard James Moore, Robert James Finlayson, James McMahon, Armin Rieger, Alexander Zoufaly, Sylvia Hartl, Robert Zangerle, Fiona Smaill, Sharon L. Walmsley, Brian Conway, Anita Rachlis, Graham H.R. Smith, Carlos Perez, Alejandro Afani, Maria Isabel Campos, Carolina Eugenia Chahin, Marcelo Wolff Reyes, Jan Gerstoft, Nina Weis, Alex Lund Laursen, Jean-Michel Molina, Yazdan Yazdanpanah, Laurent Cotte, Francois Raffi, Philippe Morlat, Pierre-Marie Girard, Christine Katlama, Juergen K. Rockstroh, Keikawus Arasteh, Stefan Esser, Albrecht Stoehr, Hans-Juergen Stellbrink, Matthias Stoll, Dirk Schuermann, Gerd Faetkenheuer, Johannes Bogner, Thomas Lutz, Axel Baumgarten, Hans Jaeger, Andrea Gori, Gabriel Coltan, Felicia Constandis, Simona Manuela Erscoiu, Liviu-Jany Prisacariu, Sorin Rugina, Adrian Streinu-Cercel, Vadim Valentinovich Pokrovsky, Natalia V. Zakharova, Andrey Anatolyevich Shuldyakov, Elena Pavlovna Ryamova, Valeriy Viktorovich Kulagin, Olga Aleksandrovna Tsybakova, Elena Orlova-Morozova, Firaya Nagimova, Evgeniy Voronin, Tatyana Evgenyevna Shimonova, Oleg Anatolyevich Kozyrev, Catherine Orrell, Johannes Jurgens Lombaard, Marleen de Jager, Joaquin Portilla Segorb, Josep Mallolas, Maria Jesus Perez Elias, Josep M. Gatell, Jose Ramon Arribas Lopez, Eugenia Negredo Puigmal, Daniel Podzamczer Palter, Federico Pulido Ortega, Jesus Troya Garcia, Ignacio De los Santos Gil, Juan Berenguer Berenguer, Ian G. Williams, Margaret A. Johnson, Gabriel Schembri, Amanda Clarke, Mark Gompels, Julie Meriel Fox, Steven John Taylor, David Harold Dockrell & Stephen Kegg. (2020) Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. The Lancet HIV 7:1, pages e16-e26.
Crossref
Crossref
Sivaporn Gatechompol, Anchalee Avihingsanon, Tanakorn Apornpong, Win Min Han, Stephen J. Kerr & Kiat Ruxrungtham. (2019) Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice. AIDS Research and Therapy 16:1.
Crossref
Crossref
Sirichai Wiriyatanakorn & Somnuek Sungkanuparph. (2019) Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine (RPV) vs Continuing TDF/FTC/EFV in HIV-infected Patients with Virological Suppression: A Randomized Controlled Trial. Open Forum Infectious Diseases.
Crossref
Crossref
Michelle A. Moorhouse & Karen Cohen. (2019) The role of rilpivirine in Southern Africa. Southern African Journal of HIV Medicine 20:1.
Crossref
Crossref
. (2019) The 2018 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infection & Chemotherapy 51:1, pages 77.
Crossref
Crossref
Alana T Brennan, Jacob Bor, Mary-Ann Davies, Gilles Wandeler, Hans Prozesky, Geoffrey Fatti, Robin Wood, Kathryn Stinson, Frank Tanser, Till Bärnighausen, Andrew Boulle, Izukanji Sikazwe, Arianna Zanolini & Matthew P Fox. (2018) Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. American Journal of Epidemiology 187:9, pages 1990-2001.
Crossref
Crossref
L Taramasso, A Di Biagio, F Maggiolo, A Tavelli, S Lo Caputo, S Bonora, M Zaccarelli, P Caramello, A Costantini, C Viscoli, A d'Arminio Monforte & A Cozzi-Lepri. (2018) First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. HIV Medicine 19:7, pages 475-484.
Crossref
Crossref
A Ocampo, P Domingo, P Fernández, J Diz, J R Barberá, M A Sepúlveda, X Salgado, M Rodriguez, J Santos, M Yzusqui, M I Mayorga, J F Lorenzo, A Bahamonde, P Bachiller, E Martínez, N Rozas, C Torres, A Muñoz, A Casado & D Podzamczer. (2018) Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study. Journal of Antimicrobial Chemotherapy 73:8, pages 2171-2176.
Crossref
Crossref
Dhwanil A. Dalwadi, Luis Ozuna, Brian H. Harvey, Michelle Viljoen & John A. Schetz. (2018) Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs. Pharmacological Reviews 70:3, pages 684-711.
Crossref
Crossref
Ali Amini, Monique Andersson, Ravindra Gupta & Brian Angus. 2018. Evidence‐Based Infectious Diseases. Evidence‐Based Infectious Diseases
149
180
.
Joanne LaFleur, Adam P. Bress, Joel Myers, Lisa Rosenblatt, Jacob Crook, Kristin Knippenberg, Roger Bedimo, Pablo Tebas, Heather Nyman & Stephen Esker. (2018) Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals. Infectious Diseases and Therapy 7:2, pages 293-308.
Crossref
Crossref
Olayemi Osiyemi, Salih Yasin, Carmen Zorrilla, Ceyhun Bicer, Vera Hillewaert, Kimberley Brown & Herta M. Crauwels. (2018) Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study. Infectious Diseases and Therapy 7:1, pages 147-159.
Crossref
Crossref
Nadia Galizzi, Laura Galli, Andrea Poli, Nicola Gianotti, Elisabetta Carini, Alba Bigoloni, Giuseppe Tambussi, Silvia Nozza, Adriano Lazzarin, Antonella Castagna, Daniela Mancusi & Roberta Termini. (2018) Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. PLOS ONE 13:2, pages e0191300.
Crossref
Crossref
Delphine Sculier, Angèle Gayet-Ageron, Manuel Battegay, Matthias Cavassini, Jan Fehr, Cedric Hirzel, Patrick Schmid, Enos Bernasconi & Alexandra Calmy. (2017) Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC Infectious Diseases 17:1.
Crossref
Crossref
D. Armenia, D. Di Carlo, A. Calcagno, G. Vendemiati, F. Forbici, A. Bertoli, G. Berno, S. Carta, F. Continenza, V. Fedele, R. Bellagamba, S. Cicalini, A. Ammassari, R. Libertone, M. Zaccarelli, V. Ghisetti, M. Andreoni, F. Ceccherini-Silberstein, S. Bonora, G. Di Perri, A. Antinori, C. F. Perno & M. M. Santoro. (2016) Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. Journal of Antimicrobial Chemotherapy, pages dkw512.
Crossref
Crossref
Jesús Troya, Pablo Ryan, Esteban Ribera, Daniel Podzamczer, Victor Hontañón, Jose Alberto Terrón, Vicente Boix, Santiago Moreno, Pilar Barrufet, Manuel Castaño, Ana Carrero, María José Galindo, Ignacio Suárez-Lozano, Hernando Knobel, Miguel Raffo, Javier Solís, María Yllescas, Herminia Esteban, Juan González-García, Juan Berenguer & Arkaitz Imaz. (2016) Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLOS ONE 11:10, pages e0164455.
Crossref
Crossref
Duncan Churchill, Laura Waters, Nadia Ahmed, Brian Angus, Marta Boffito, Mark Bower, David Dunn, Simon Edwards, Carol Emerson, Sarah Fidler, Martin Fisher, Rob Horne, Saye Khoo, Clifford Leen, Nicola Mackie, Neal Marshall, Fernando Monteiro, Mark Nelson, Chloe Orkin, Adrian Palfreeman, Sarah Pett, Andrew Phillips, Frank Post, Anton Pozniak, Iain Reeves, Caroline Sabin, Roy Trevelion, John Walsh, Ed Wilkins, Ian Williams & Alan Winston. (2016) British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Medicine 17, pages s2-s104.
Crossref
Crossref
Dhwanil A. Dalwadi, Seongcheol Kim, Shahnawaz M. Amdani, Zhenglan Chen, Ren-Qi Huang & John A. Schetz. (2016) Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz. Pharmacological Research 110, pages 10-24.
Crossref
Crossref
Rosario Palacios, Marisa Mayorga, Isabel A. Pérez-Hernández, Antonio Rivero, Alfonso del Arco, Fernando Lozano & Jesús Santos. (2016) Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet. Journal of the International Association of Providers of AIDS Care (JIAPAC) 15:3, pages 189-193.
Crossref
Crossref
Kerri J. Penrose, Urvi M. Parikh, Kristen A. Hamanishi, Laura Else, David Back, Marta Boffito, Akil Jackson & John W. Mellors. (2016) Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). Journal of Infectious Diseases 213:6, pages 1013-1017.
Crossref
Crossref
Jan van Lunzen, Andrea Antinori, Calvin J. Cohen, José R. Arribas, David A. Wohl, Armin Rieger, Anita Rachlis, Mark Bloch, Sorana Segal-Maurer, Will Garner, Danielle Porter, Matthew Bosse, David Piontkowsky, Susan K. Chuck & Shampa De-Oertel. (2016) Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults. AIDS 30:2, pages 251-259.
Crossref
Crossref
E Pedrol, JM Llibre, M Tasias, A Currán, JM Guardiola, E Deig, A Guelar, O Martínez-Madrid, L Tikhomirova & R Ramírez. (2015) Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. HIV Medicine 16:10, pages 628-634.
Crossref
Crossref
. (2015) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos con infección por el virus de la inmunodeficiencia humana (Actualización enero 2015). Enfermedades Infecciosas y Microbiología Clínica 33:8, pages 543.e1-543.e43.
Crossref
Crossref
David A Margolis, Cynthia C Brinson, Graham H R Smith, Jerome de Vente, Debbie P Hagins, Joseph J Eron, Sandy K Griffith, Marty H St Clair, Marita C Stevens, Peter E Williams, Susan L Ford, Britt S Stancil, Melinda M Bomar, Krischan J Hudson, Kimberly Y Smith & William R Spreen. (2015) Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. The Lancet Infectious Diseases 15:10, pages 1145-1155.
Crossref
Crossref
Emma D. Deeks. (2015) Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen in HIV-1 infection: a guide to its use in the EU. Drugs & Therapy Perspectives 31:8, pages 251-258.
Crossref
Crossref
David A. Margolis & Marta Boffito. (2015) Long-acting antiviral agents for HIV treatment. Current Opinion in HIV and AIDS 10:4, pages 246-252.
Crossref
Crossref
Corinne Isnard Bagnis & Hans-Jürgen Stellbrink. (2015) Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review. Infectious Diseases and Therapy 4:1, pages 15-50.
Crossref
Crossref
P Gantner, S Reinhart, M Partisani, M Baldeyrou, M-L Batard, C Bernard-Henry, C Cheneau, E de Mautort, M Priester, S Fafi-Kremer, P Muret & D Rey. (2015) Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study. HIV Medicine 16:2, pages 132-136.
Crossref
Crossref
Anna Maria Geretti & Maria Tsakiroglou. (2014) HIV. Current Opinion in Infectious Diseases 27:6, pages 545-553.
Crossref
Crossref
C. Amiel, V. Schneider, S. Guessant, M. Hamidi, K. Kherallah, M.-G. Lebrette, J. Chas, C. Lependeven & G. Pialoux. (2014) Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'. Journal of Antimicrobial Chemotherapy 69:12, pages 3335-3339.
Crossref
Crossref
. (2014) International Congress of Drug Therapy in HIV Infection 2-6 November 2014, Glasgow, UK. Journal of the International AIDS Society 17, pages 19856.
Crossref
Crossref
Isabel A Pérez‐Hernández, Rosario Palacios, Marisa Mayorga, Carmen M González‐Doménech, Manuel Castaño, Antonio Rivero, Alfonso del Arco, Fernando Lozano & Jesús Santos. (2014)
Lipid changes in HIV‐patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera
®
). Efficacy and safety analysis. GeSida Study 8114
. Journal of the International AIDS Society 17:4S3.
Crossref
Crossref
A. Blas-Garcia, M. Polo, F. Alegre, H. A. Funes, E. Martinez, N. Apostolova & J. V. Esplugues. (2014) Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz. Journal of Antimicrobial Chemotherapy 69:11, pages 2995-3000.
Crossref
Crossref
Emma D. Deeks. (2014) Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Review of Its Use in HIV Infection. Drugs 74:17, pages 2079-2095.
Crossref
Crossref
C. Allavena, E. Dailly, V. Reliquet, B. Bonnet, S. Pineau, E. Andre-Garnier, D. Boutoille, R. Bouquie, A. Raveleau, S. Bouchez, E. Billaud & F. Raffi. (2014) Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. Journal of Antimicrobial Chemotherapy 69:10, pages 2804-2808.
Crossref
Crossref
Dipen A. Patel, Sonya J. Snedecor, Wing Yu Tang, Lavanya Sudharshan, Jessica W. Lim, Robert Cuffe, Sonia Pulgar, Kim A. Gilchrist, Rodrigo Refoios Camejo, Jennifer Stephens & Garrett Nichols. (2014) 48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis. PLoS ONE 9:9, pages e105653.
Crossref
Crossref
Alice K. Pau & Jomy M. George. (2014) Antiretroviral Therapy. Infectious Disease Clinics of North America 28:3, pages 371-402.
Crossref
Crossref
Sophie Herbert, Emily Chung & Laura Waters. (2014) HIV Treatment. Current Treatment Options in Infectious Diseases 6:3, pages 271-293.
Crossref
Crossref
. (2014) Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2014). Enfermedades Infecciosas y Microbiología Clínica 32:7, pages 446.e1-446.e42.
Crossref
Crossref
Marta Boffito, Akil Jackson, Andrew Owen & Stephen Becker. (2013) New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. Drugs 74:1, pages 7-13.
Crossref
Crossref